The Sandoz product will be marketed in Japan as Somatropin BS S.C. injection 5mg / 10mg.
It is approved for the treatment of growth hormone deficiency in children and growth disturbance associated with Turner's syndrome or chronic renal insufficiency.
Sandoz somatropin already marketed as Omnitrope in EU, US and Australia.
Sandoz is a Division of the Novartis group.<헬스코리아뉴스>
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지